Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acumen Pharmaceuticals, Inc. filings document a clinical-stage biopharmaceutical issuer focused on Alzheimer’s disease programs targeting toxic soluble amyloid beta oligomers. Its Form 8-K reports include operating and financial results, business highlights, Regulation FD presentation updates, clinical and nonclinical program disclosures, and material agreements related to Enhanced Brain Delivery development.
Proxy materials describe annual meeting voting matters, board elections, auditor ratification, and equity incentive plan approvals. The filing record also discloses ABOS common stock registered on the Nasdaq Global Select Market, emerging growth company status, governance changes, capital-structure matters, and clinical and regulatory disclosure categories tied to drug development.
Acumen Pharmaceuticals, Inc. reported results of its 2026 annual stockholder meeting. Stockholders elected three Class II directors to serve until the 2029 annual meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders also approved the Company’s Amended and Restated 2021 Equity Incentive Plan. Quorum was strong, with 57,051,456 of 72,227,580 shares outstanding, or approximately 78.99%, present or represented by proxy at the meeting.
Acumen Pharmaceuticals reported a smaller quarterly loss while highlighting funding risk. For the three months ended March 31, 2026, the company recorded a net loss of $20.7 million, improving from $28.8 million a year earlier, as research and development spending decreased to $16.5 million from $25.3 million with lower manufacturing and CRO costs for its ALTITUDE-AD Phase 2 trial.
General and administrative expenses declined modestly to $4.7 million. Acumen ended the quarter with cash, cash equivalents and marketable securities totaling $128.4 million and completed a private placement of 10,833,331 shares at $3.30 per share for gross proceeds of about $35.7 million. Management expects these resources to fund operations into early 2027 but concluded that substantial doubt exists about its ability to continue as a going concern without additional capital.
Development remains centered on sabirnetug, an Aß oligomer–targeting antibody in the Phase 2 ALTITUDE-AD trial, with top-line results planned for late 2026, alongside a subcutaneous formulation and an Enhanced Brain Delivery (EBD™) program targeting an IND filing around mid‑2027.
Acumen Pharmaceuticals reported first quarter 2026 results and updated progress on its Alzheimer’s programs. Cash, cash equivalents and marketable securities were $128.4 million as of March 31, 2026, up from $116.9 million at December 31, 2025, helped by a March private placement that generated $35.75 million in gross proceeds. Management expects this cash to fund current clinical and operational activities into early 2027.
R&D expenses fell to $16.5 million from $25.3 million a year earlier as ALTITUDE-AD Phase 2 enrollment completed, while G&A declined to $4.7 million from $5.1 million. Net loss narrowed to $20.7 million from $28.8 million, or $0.33 per share. The company reiterated plans to report topline Phase 2 ALTITUDE-AD data for sabirnetug in late 2026 and to target an IND filing for a lead EBD enhanced brain-delivery candidate in mid-2027.
Acumen Pharmaceuticals is holding a virtual 2026 annual meeting on June 3, 2026 to elect three Class II directors, ratify Ernst & Young LLP as auditor for 2026, and approve an Amended and Restated 2021 Equity Incentive Plan.
The equity plan proposal would add 10,000,000 shares of common stock to the pool, remove the automatic “evergreen” increase, and explicitly prohibit repricing of stock options or stock appreciation rights without stockholder approval, other than in certain corporate transactions. As of April 8, 2026, 72,227,580 common shares were outstanding and entitled to vote.
Acumen Pharmaceuticals, Inc. Schedule 13G reports that James B. Murray Jr. beneficially owned 3,611,360 shares of common stock as of April 6, 2026, representing 5.00% of outstanding common stock based on a 72,212,758 share denominator. The filing breaks ownership into 3,468,465 shares held in Mr. Murray's revocable trust and 142,895 shares held by Praxis Technologies LLC; Mr. Murray is a manager of Praxis and shares voting/dispositive power for those shares.
Acumen Pharmaceuticals, Inc. is registering 10,833,331 shares of Common Stock for resale by selling stockholders that acquired the shares in a March 16, 2026 private placement. The prospectus states the company will not receive proceeds from these resales and that the selling stockholders will determine timing, price and method of disposition.
The prospectus notes 72,212,758 shares outstanding as of March 20, 2026 and discloses a March 31, 2026 last reported sale price of $2.36 per share. The registration is part of an S-3 shelf process and includes customary plan-of-distribution provisions and registration-rights obligations.
Acumen Pharmaceuticals, Inc. is registering the resale of up to 10,833,331 shares of its common stock.
This prospectus covers shares issued in a Private Placement completed on March 16, 2026 at $3.30 per share; the Company will not receive proceeds from resales. The Registration Rights Agreement commits the Company to keep the registration statement effective until the selling stockholders have resold the registrable securities or they can be resold under Rule 144.
Context: shares outstanding were 72,212,758 as of March 20, 2026, the Company’s common stock trades on Nasdaq Global Select (symbol ABOS), and the last reported sale price was $2.63 on March 25, 2026. The prospectus lists the selling stockholders and the permitted distribution methods; the Company will bear registration expenses.
Acumen Pharmaceuticals is a clinical-stage biopharma company focused on Alzheimer’s disease. Its lead and only clinical product candidate, sabirnetug (ACU193), is an Aβ oligomer–selective monoclonal antibody in the Phase 2 ALTITUDE-AD trial in early Alzheimer’s, with topline results expected in late 2026.
Phase 1 INTERCEPT-AD in early Alzheimer’s patients met primary and secondary objectives, showing dose-related amyloid plaque reduction, near-maximal target engagement at higher doses and an overall ARIA-E rate of 10.4%. The company is also advancing subcutaneous sabirnetug and a blood-brain barrier–penetrating EBD™ program, and has collaborations with Halozyme, JCR and Lonza. Acumen discloses substantial funding needs and an auditor “going concern” explanatory paragraph, and highlights heavy dependence on sabirnetug amid intense competition in Alzheimer’s therapies.